Aside from the mere fact that this thing is under a buck should not surprise anyone. Just keep in mind that from we know of Zalicus has way more positive indicators then negative ones, big time. When being invested in Zalicus you must realize that this is no Apple, Costco or J&J, which by the way is much easier to sleep with at night. Zalicus will deliver positive results which will spur a whole lot of interest in the shares during October and beyond. Look for shares to move higher between now and the end of this month. I'm thinking in the range of 0.83 to 0.92. To $1 and some change as we approach October, and $2.47 to $3 a share after positive data is announced.
Remember, Novartis has exercised its third option to extend its oncology discovery research collaboration with Zalicus for an additional contract year, through October 2014. This in it's self holds tremendous weight.